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ABSTRACT 
Cognitive deficits in schizophrenia have major functional impacts. Modafinil is a cognitive 
enhancer whose effect in healthy volunteers is well-described, but whose effects on the 
cognitive deficits of schizophrenia appear to be inconsistent. Two possible reasons for this are 
that cognitive test batteries vary in their sensitivity, or that the phase of illness may be 
important, with patients early in their illness responding better. A double-blind, randomised, 
placebo-controlled single-dose crossover study of modafinil 200mg examined this with two 
cognitive batteries (MCCB and CANTAB) in 46 participants with under 3 years’ duration of 
DSM-IV schizophrenia, on stable antipsychotic medication. In parallel, the same design was 
used in 28 age-, sex-, and education-matched healthy volunteers. Uncorrected p values were 
calculated using mixed effects models. In patients, modafinil significantly improved CANTAB 
Paired Associate Learning, non-significantly improved efficiency and significantly slowed 
performance of the CANTAB Stockings of Cambridge spatial planning task. There was no 
significant effect on any MCCB domain. In healthy volunteers, modafinil significantly 
increased CANTAB Rapid Visual Processing, Intra-Extra Dimensional Set Shifting and verbal 
recall accuracy, and MCCB social cognition performance. The only significant differences 
between groups were in MCCB visual learning. In conclusion, as in earlier chronic 
schizophrenia studies, modafinil failed to produce changes in cognition in early psychosis as 
measured by MCCB. CANTAB proved more sensitive to the effects of modafinil in 
participants with early schizophrenia and in healthy volunteers. This confirms the importance 
of selecting the appropriate test battery in treatment studies of cognition in schizophrenia. 
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1. INTRODUCTION 
Cognitive impairment, a core feature of schizophrenia, accounts for 20-60% of variance in 
functional outcome (Green, 1996). From infancy to early adulthood development of many 
cognitive functions is delayed (Reichenberg et al., 2010), perhaps with deterioration before 
first episode (Caspi et al., 2003) but then the cognitive function of patients with schizophrenia 
decline little or no faster than healthy populations until late middle age (Censits et al., 1997, 
Irani et al., 2012). Milder deficits in clinically unaffected relatives indicate a genetic 
contribution (Goldberg et al., 1990, Cannon et al., 1994) but the pathophysiological basis of 
cognitive deficits remain unclear (Harvey et al., 2001). Pharmacological cognition enhancers 
(CEs), like modafinil, have been used to investigate potential beneficial effects on cognitive 
domains and also the underlying mechanisms of cognitive deficits. 
 
In healthy volunteers without sleep deprivation, larger studies (n>40) provide moderately 
consistent evidence of effects of modafinil, though often on the basis of uncorrected 
significance testing of multiple domains (Turner et al., 2003, Randall et al., 2005, Müller et al., 
2013, Mohamed and Lewis, 2014). These include: decreased latency on delayed match to 
sample, stop signal and Stroop basic recognition tasks, more accurate rapid visual processing, 
spatial working memory, planning (Stockings of Cambridge task) and pattern recognition 
memory; but slower completion of the Hayling and clock completion tasks. Many such studies 
have used the Cambridge Neuropsychological Test Automated Battery (CANTAB; 
www.camcog.com) - a well validated computerised battery which is easily compared to 
analogous animal task data (Robbins et al., 1994, 1998, Randall et al., 2003, 2004, 2005, Turner 
et al., 2003, Müller et al., 2013). Modafinil may have a greater effect on scores in samples with 
lower IQ or greater age, perhaps because these studies avoided ceiling effects (Randall et al., 
2005). 
 
A few modafinil trials in schizophrenia have also used CANTAB and modafinil’s effects 
loosely resemble those in healthy volunteers, though studies are often smaller and again rely 
on uncorrected statistics. Scoriels and colleagues’ (2012) single-dose, cross-over comparison 
of modafinil to placebo in 40 first-episode psychosis patients found significantly improved 
working memory, spatial working memory accuracy and strategy; fewer discrimination errors 
in the impulsivity task; and better facial emotion recognition (Scoriels et al., 2011). Turner et 
al.’s (2004) cross-over trial of twenty patients with chronic schizophrenia reported increased 
latency but more efficient solutions for the Stockings of Cambridge task, and fewer 
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extradimensional shift (EDS) errors during the set shifting task. Overall these results suggest 
that modafinil has some beneficial effects on short term memory and attention, as well as on 
planning and set shifting in schizophrenia, although the mechanism of action is disputed and 
unclear (Gerrard and Malcolm, 2007, Battleday and Brem, 2015). This is arguably consistent 
with imaging studies which show increased anterior cingulate and dorsolateral prefrontal 
activation during cognitive and motor control tasks (Spence et al., 2005, Hunter et al., 2006). 
Conversely, small, less powerful parallel-arm studies found no effects of modafinil on 
cognition (Sevy et al., 2005, Pierre et al., 2007). 
 
Only one trial has evaluated modafinil in schizophrenia using the MATRICS Consensus 
Cognitive Battery (MCCB) (Michalopoulou et al., 2015). The MCCB has the advantages that 
it is accepted as a viable endpoint measure for clinical trials by the FDA, was developed 
specifically for use in schizophrenia, and has extensive normative data. Unlike CANTAB, 
MCCB’s administration is heavily language based, and it is not derived from equivalent 
animal data (Kern et al., 2008, Nuechterlein et al., 2008). In this trial, Michalopoulou et al. 
(2015) found no significant effect of modafinil on MCCB domain or composite scores or 
CogState SB (a computer-based battery) in a sample of 48 participants with chronic 
schizophrenia, mean age 37.2+9.6 years.  Many factors could have contributed to the absence 
of a measurable effect of modafinil on cognition: (i) modafinil does not enhance cognition in 
schizophrenia, (ii) modafinil enhances cognition in early schizophrenia but not chronic 
schizophrenia, or (iii) modafinil enhances cognition but the assessment batteries used are not 
sufficiently sensitive to detect changes over time.   
 
To distinguish these explanations the current study examined participants in the early stages of 
schizophrenia with both the CANTAB and MCCB. Our main hypothesis was that compared to 
placebo, modafinil would have similar effects on cognition in early schizophrenia and healthy 
volunteers, and hence would normalise deficits in planning strategy, working memory, set 
shifting and social cognition in early schizophrenia, measured against healthy volunteers’ 
baseline. A secondary hypothesis, that choice of cognitive battery would be an important factor 
in detecting modafinil-induced change in both patients and healthy volunteers, was tested by 
comparing CANTAB and MCCB batteries. 
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2. METHOD 
We used a double blind randomised placebo-controlled crossover design to compare the 
effects of modafinil in participants with early schizophrenia and related disorders, and  in 
matched healthy volunteers. The study in schizophrenia received ethical approval from the 
Greater Manchester South Research Ethics Committee and the extension to healthy 
volunteers from Greater Manchester East Research Ethics Committee East (REC numbers 
13/NW/0626 and 14/NW/0299).  
 
Participants 
Patients aged between 18 and 35 years old were recruited from mental health services of 
King’s Health Partners’ (London) and Manchester Academic Health Science Centre. 
Inclusion criteria were: (i) DSM-IV criteria for schizophrenia, schizophreniform or 
schizoaffective disorder (confirmed using the Mini International Neuropsychiatric Interview 
(Sheehan et al., 1998)); (ii) clinically stable in a non-acute phase for at least 8 weeks prior to 
the screening visit with duration of illness between one month and three years; (iii) treated 
with stable doses of 2nd generation antipsychotics (excluding clozapine) in the absence of 
concomitant anticholinergics for a minimum of 4 weeks prior to screening; (iv) a score of <5 
on the PANSS conceptual disorganisation, hallucinations, unusual thought content and all 
negative subscale items; (v) English at a level sufficient to understand and complete study-
related procedures, and score >6 on the Wechsler Test of Adult Reading (Holdnack, 2001). 
Female participants of child-bearing potential were required to use an acceptable method of 
contraception for the duration of the study and have a negative pregnancy test result at 
screening. 
 
Participants were excluded from the study if they met DSM-IV criteria for alcohol or 
substance abuse (other than nicotine) within the last month or dependence in the last six 
months preceding the screening visit. They were also excluded if they were being treated 
with modafinil, agents known to affect cognition (including anticholinergics, clozapine and 
thioridazine), compounds known to interact with modafinil, or any known drug allergies; a 
history of significant head trauma, or a serious neurological disorder; an abnormal ECG or 
physical examination findings; or participation in a study of any psychotropic medication or 
with a neuropsychological component in the two months preceding the screening visit. 
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For healthy volunteers (HVs), age and literacy inclusion criteria and all exclusion criteria 
were identical. HVs were matched to those in the first group on age (+ 5 years), gender, 
ethnicity and years of education. 
 
 
Procedure 
Thirty six HVs and 65 participants with schizophrenia attended visit 1, during which they 
gave written informed consent, followed by a check of their eligibility. Of these, 28 HVs and 
46 schizophrenia patients were confirmed as eligible and included in the double-blind, 
placebo-controlled, single-dose cross-over study. Two HVs and 6 schizophrenia participants 
withdrew following randomisation; a further 5 HVs were withdrawn due to an adverse event 
or because they were unable to complete the study within the timeframe required.  
 
Participants subsequently attended three neuropsychological assessment visits (visits 2-4). 
They received medication on the day of visits 3 and 4, 2 hours prior to assessment, namely 
200mg modafinil on one occasion and an identical placebo tablet at the other visit, in random 
order. Visits 3 and 4 occurred seven to ten days apart to allow a wash-out period. 
 
Drug Treatment 
The dose of 200mg of modafinil was chosen after reviewing pharmacokinetic studies of 
modafinil and previous studies of modafinil in healthy volunteers (Wong et al., 1999a, 
1999b) and in patients with schizophrenia (Turner et al., 2004, Rosenthal and Bryant, 2004, 
Sevy et al., 2005, Spence et al., 2005, Hunter et al., 2006, Pierre et al., 2007). Participants 
were told to take the tablet two hours before their appointment and reminded by telephone at 
the appropriate time, in order that peak plasma levels were reached during assessment, 2-3hrs 
after oral administration (Wong et al., 1999a, 1999b). Vital signs were recorded at all 4 visits 
and adverse effects monitored at all visits and by telephone 7-10 days after visit 4. 
 
Allocation 
Allocation, carried out via an online system at the King’s Clinical Trials Unit, was by 
minimisation. Smoking status (known to effect cognitive performance) (Lees et al., 2015) and 
treatment site (to allow for possible  differences) were used as stratifying factors. Capsules 
were supplied in coded bottles containing identical capsules of modafinil and placebo. 
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Cognitive Tests 
Participants completed the MATRICS Consensus Cognitive Battery (MCCB (Kern et al., 
2008, Nuechterlein et al., 2008)) and CANTAB Schizophrenia Battery (www.camcog.com). 
Alternative forms of tests were used at the different visits if they were sensitive to practice 
effects: these included the MCCB Brief Visuospatial Memory Test-Revised (BVMT-R), 
Hopkins Verbal Learning Test-Revised (HVLT-R) and Neuropsychological Assessment 
Battery (NAB) mazes, and the CANTAB Verbal Recognition Memory (VRM), Paired 
Associates Learning (PAL) and Intra/extradimensional Set Shift (IED).  
 
Statistical Analysis 
To test the hypothesis that modafinil in patient participants would increase scores on specific 
tests towards healthy baselines,  we assumed there were no carryover effects due to the wash-
out period, but we allowed for period (i.e. time) and sequence effects, whilst our primary 
effect of interest was the treatment effect (i.e. modafinil versus placebo). We use random 
effect models with a fixed effect for period and treatment, and a random intercept for each 
participant.  The treatment effect for each outcome was given by a model coefficient, and 
associated standard error, p-value, and 95% confidence intervals. The effect interpreted was 
the change in outcome associated with receiving modafinil compared to receiving placebo. 
 
To compare the healthy volunteer and patient samples and test the prediction that modafinil 
would affect the two groups similarly, we analyse both studies together using the model 
described above, with the addition of a fixed effect term for study and an interaction between 
study and drug.  The interaction tests whether the treatment effect differs between the 
samples.  The interaction shows the difference in the effect of receiving modafinil compared 
to placebo, in the healthy volunteers compared to the patient sample. 
 
Across both analyses p values were uncorrected for each test, following Rothman (1990). 
95% Confidence Intervals (CI) were calculated. Standardized treatment effect sizes were 
expressed as Glass’ δ, final score mean difference between modafinil and placebo divided by 
the final standard deviation for placebo. 
 
3. RESULTS 
Of 28 eligible controls, 21 (75%) completed all test sessions. Of 46 eligible schizophrenia 
patients, 40 (87%) completed all test sessions. Fourteen (33%) controls and 23 (57.5%) 
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patients smoked; 15 (71%) controls and 30 (75%) patients were male. Age and full-time 
education were similar across both groups (Table 1). Verbal IQ as represented by WTAR 
standardised score differed with effect size -0.81 (Glass’ δ, using healthy volunteer SD). 
Tables S1 and 2 show baseline CANTAB and MCCB scores for the schizophrenia and 
healthy volunteer groups. Healthy volunteer mean MCCB composite T-scores were 45.2 (SD 
10.5), while patients’ scores were mean 28.8 (SD 13.0), showing a global deficit of δ-1.26. 
 
There was no significant effect of modafinil on patients’ MCCB scores (Figure 1, Tables 2 
and S3), though working memory showed a trend towards improvement (1.80, CI -0.09, 3.69; 
p0.06). Examining patients’ CANTAB scores after modafinil (Figure 1, Tables 2 & S4), 
patients reached solutions for the OTS planning task in non-significantly fewer steps but 
significantly more slowly (median latency 3.3 seconds more; 95% CI 0.8, 5.8). Modafinil-
treatment also resulted in significantly fewer errors on the PAL visual learning task (6 shapes, 
p0.015). 
 
Healthy volunteers had significantly improved scores after modafinil on the MCCB social 
cognition domain (5.04, CI 2.23, 7.86, p<0.001), and trends towards better scores for visual 
learning (2.21; CI -0.39, 4.80; p0.095) and global MCCB (composite score 1.63, CI -0.23, 
3.48, p0.085; Figure 1, Tables 3 & S5). They significantly improved on some CANTAB 
measures of set shifting (IED adjusted errors, p0.008), rapid visual information processing 
(RVP A, p0.004; and hit probability, p0.001), and verbal recognition memory (VRM 
immediate free recall novel words, p0.028; Figure 1, Tables 3 and S6).  
 
To examine the prediction that volunteers with and without schizophrenia would respond 
similarly to modafinil we examined interactions between response to modafinil and group. 
On the MCCB visual learning healthy volunteers were significantly more responsive to 
modafinil than patients (4.89; CI 0.07, 9.71; p0.047). There were no other significant 
differences in MCCB domains or on the CANTAB task scores (Tables 4 & S7), though 
patients displayed  trends towards more slowing of OTS completion after modafinil (-3.66 
sec, CI -7.41, 0.08, p0.055) and greater improvement in RVP probability of a hit (0.05, CI -
0.01, 0.11, p0.097). 
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4. DISCUSSION 
The primary hypothesis was that modafinil would produce improvements in spatial planning, 
working memory, set shifting and social cognition, normalising these deficits in early 
schizophrenia. This hypothesis of specific improvements was not consistently supported in 
this single-dose crossover study. Though one measure of visual learning (PAL errors on 
CANTAB) improved, there was no significant effect on other CANTAB or MCCB measures 
of working memory or planning efficiency (e.g. the One Touch Stockings task or the MCCB 
problem solving domain). However, patients made choices on the Stockings task significantly 
more slowly after modafinil (i.e. OTS latency increased), an effect previously seen in healthy 
volunteers (Turner et al., 2003, Randall et al., 2005, Mohamed and Lewis, 2014), with a trend 
towards a decrease in OTS choices to correct, suggesting a speed/error trade-off, bringing 
patient’s scores closer to those of healthy volunteers at baseline. On the other hand, healthy 
volunteers improved in their social cognition performance, an effect previously seen in early 
schizophrenia (Scoriels et al., 2012), while here patients did not.  
 
To test whether HVs and patients responded to modafinil in a similar way, which would 
suggest that the drug has similar mechanisms in both, an interaction term was added for drug 
and group (i.e. modafinil and patient) to models of the main effects of group (HV or patient) 
and drug (baseline, placebo or modafinil) with appropriate adjustment for session (baseline, 
first or second follow-up) on the various neurocognitive measures. Confidence intervals were 
wide, given the limited numbers and we found only one significant difference in modafinil’s 
effect on schizophrenia and HV groups:  a significant difference in MCCB visual learning, 
where healthy volunteers but not patients improved  (Table 4). Admittedly, the positive 
finding could just be an artefact of multiple hypothesis testing. Alternatively, the MCCB 
domain score could be more sensitive to rapid processing than the CANTAB’s PAL task, 
since like the MCCB domain score some CANTAB rapid visual processing (RVP) measures 
improved in HV but not patients. The results are consistent with those of previous studies 
investigating the effects of modafinil, including  improved performance on the same visual 
processing measures in healthy volunteers (Randall et al., 2005), an effect not demonstrated 
in schizophrenia sufferers (Scoriels et al., 2012), and an improvement in the OTS spatial 
planning task (Turner et al., 2003, Turner et al., 2004, Müller et al., 2013). 
 
Healthy volunteers also differed from patients in that modafinil improved their social 
cognition task performance. Between the two batteries this is tested by one task, the 
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MSCEIT, with several elements (Kern et al., 2008, Nuechterlein et al., 2008). The complexity 
of the MSCEIT, which like many social cognitive tasks has appreciable demands on working 
memory and other executive functions, makes this difficult to compare to the tasks that 
Scoriels’ group used (2012), and could suggest the MSCEIT may not be the best task to use 
since schizophrenia sufferers might have difficulties performing the MSCEIT due to 
executive function deficits, if the task is a measure of executive function rather than social 
cognition. 
 
An important limitation is the multiplicity of tests and the consequent impracticability of 
correction of p values. This is further complicated by its being unclear how much scores on 
any particular test will vary with scores on another, making independence of scores uncertain. 
This makes cautious interpretation of the results a necessity, but the approach taken across 
the field is to make such exploratory analyses at this early stage of investigation of the drug’s 
relative impact in different groups. In addition, the use of a single dose may have been 
insufficient in patients to allow the full effects of modafinil to accrue. Our previous study 
entailed 2 weeks’ cognitive training while prescribed modafinil or placebo. 
Do explanations in the literature for differences in the effects of modafinil on various samples 
based on lack of cognitive reserve or ceiling effects on tasks (Randall et al., 2005, Müller et 
al., 2013) apply here? The healthy volunteer sample was well matched on IQ and education, 
when compared to some previous samples. Despite this patients with limitations in executive 
function (or other aspects of cognition) may have been restricted in their ability to improve 
performance on other tasks following modafinil if executive function deficits impaired 
performance on other tasks that required executive processing to enable high level 
performance of core skills. 
Comparing the two batteries, CANTAB proved more sensitive to changes in visual learning 
and processing that emerged only at trend levels of significance with MCCB. CANTAB was 
also able to identify changes in speed of planning that the MCCB, being paper-and-pencil 
based, cannot.  At present the standard CANTAB schizophrenia battery lacks social and 
emotional processing measures that the MCCB includes, but the credentials of the MCCB as 
the pre-eminent tool for investigating neurocognitive performance are not unequivocally 
endorsed by these results.  
Conclusions 
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Given the inconsistency of findings concerning modafinil in schizophrenia(Scoriels et al., 
2012, 2013, Michalopoulou et al., 2015, Vreeker et al., 2015)  the present study was mounted 
to test whether phase of illness was critical for the action of cognitive enhancers. We also 
compared cognitive assessment batteries’ sensitivities.  Here, modafinil significantly 
improved visual learning and processing as assessed by CANTAB, but not MCCB, in 
patients with early schizophrenia. It also led to slower performance during one CANTAB 
task . Effect sizes were often larger in the CANTAB and it had the capacity to detect effects 
on speed of performance, but the MCCB was able to detect changes in social cognition the 
CANTAB tasks used in this study could not. We conclude that whereas phase of illness may 
not be crucial to demonstrating the action of cognitive enhancers, the selection of assessment 
instrument may be. This has implications for clinical trial design in this important therapeutic 
area.  
The complexity of modafinil’s actions and the multiplicity of tests prevent firm conclusions. 
Tentatively, one can suppose that modafinil improved certain aspects of healthy volunteers’ 
performance more than patients’, but any such differences were too small to reach 
significance in most domains. Patients, unlike healthy volunteers, showed no significant 
benefit to visual processing or efficiency of strategic cognition, suggesting specific 
differences between the two groups. Otherwise,  the fact that there are similar findings in 
each group across this and other studies is most easily explained by a fundamentally similar 
effect of modafinil in health and early illness across several areas of cognition. Larger studies 
or evidence from more direct investigation of the mechanisms of modafinil in health and 
schizophrenia, for instance by brain imaging, would be needed to establish this. 
 
 
  
12 
 
Acknowledgements 
We acknowledge the support of the NIHR/Wellcome Trust Clinical Research Facility, 
Manchester, and the NIHR Biomedical Research Centre for Mental Health at the South 
London and Maudsley NHS Foundation Trust, the participants, and NEWMEDS. The 
research leading to these results has received support from the Innovative Medicines 
Initiative Joint Undertaking under grant agreement n° 115008 of which resources are 
composed of EFPIA in-kind contribution and financial contribution from the European 
Union’s Seventh Framework Programme (FP7/2007-2013). 
 
Financial Support 
Funding for this study was provided by EU Innovative Medicines Initiative to the 
NEWMEDS programme (grant number 115008); the European Commission had no further 
role in study design; in the collection, analysis and interpretation of data; in the writing of the 
report; and in the decision to submit the paper for publication. 
 
Conflict of Interest 
Prof Kapur has received grant support from AstraZeneca, Bristol-Myers Squibb and 
GlaxoSmthKline and has served as consultant, scientific advisor and had speaking 
engagements for AstraZeneca, Bioline, Bristol Meyers Squibb, Eli Lilly, Janssen (Johnson 
and Johnson), Lundbeck, NeuroSearch, Otsuka, Pfizer, Roche, Servier, Solvay and Wyeth. 
Dr. Pandina is a full time employee of Janssen Research & Development and is a Johnson & 
Johnson stock-holder. 
Prof Lewis has received consultancy fees from AbbVie, and Johnson and Johnson. 
All other authors declare no competing interests. 
 
Ethical Standards 
The authors assert that all procedures contributing to this work comply with the ethical 
standards of the relevant national and institutional committees on human experimentation and 
with the Helsinki Declaration of 1975, as revised in 2008. 
 
 
  
13 
 
REFERENCES 
Battleday, R. M. & Brem, A. K. (2015). Modafinil for cognitive neuroenhancement in 
healthy non-sleep-deprived subjects: A systematic review. European 
Neuropsychopharmacology, 25, 1865-1881. 
Cannon, T. D., Zorrilla, L. E., Shtasel, D., Gur, R. E., Gur, R. C., Marco, E. J., Moberg, 
P. & Price, R. A. (1994). Neuropsychological functioning in siblings discordant for 
schizophrenia and healthy volunteers. Archives of General Psychiatry, 51, 651-61. 
Caspi, A., Reichenberg, A., Weiser, M., Rabinowitz, J., Kaplan, Z., Knobler, H., 
Davidson-Sagi, N. & Davidson, M. (2003). Cognitive performance in schizophrenia 
patients assessed before and following the first psychotic episode. Schizophrenia 
Research, 65, 87-94. 
Censits, D. M., Ragland, J. D., Gur, R. C. & Gur, R. E. (1997). Neuropsychological 
evidence supporting a neurodevelopmental model of schizophrenia: a longitudinal 
study. Schizophrenia Research, 24, 289-98. 
Gerrard, P. & Malcolm, R. (2007). Mechanisms of modafinil: A review of current research. 
Neuropsychiatric Disease and Treatment, 3. 
Goldberg, T. E., Ragland, J. D., Torrey, E. F., Gold, J. M., Bigelow, L. B. & 
Weinberger, D. R. (1990). Neuropsychological assessment of monozygotic twins 
discordant for schizophrenia. Archives of General Psychiatry, 47, 1066-72. 
Green, M. F. (1996). What are the functional consequences of neurocognitive deficits in 
schizophrenia? American Journal of Psychiatry, 153, 321-30. 
Harvey, P. D., Bowie, C. R. & Friedman, J. I. (2001). Cognition in schizophrenia. Current 
Psychiatry Reports, 3, 423-8. 
Holdnack, H. (2001). Wechsler Test of Adult Reading: WTAR. San Antonio, TX: Harcourt 
Assessment. 
Hunter, M. D., Ganesan, V., Wilkinson, I. D. & Spence, S. A. (2006). Impact of modafinil 
on prefrontal executive function in schizophrenia. American Journal of Psychiatry, 
163, 2184-6. 
Irani, F., Brensinger, C. M., Richard, J., Calkins, M. E., Moberg, P. J., Bilker, W., Gur, 
R. E. & Gur, R. C. (2012). Computerized neurocognitive test performance in 
schizophrenia: a lifespan analysis. American Journal of Geriatric Psychiatry, 20, 41-
52. 
Kern, R. S., Nuechterlein, K. H., Green, M. F., Baade, L. E., Fenton, W. S., Gold, J. M., 
Keefe, R. S., Mesholam-Gately, R., Mintz, J., Seidman, L. J., Stover, E. & 
Marder, S. R. (2008). The MATRICS Consensus Cognitive Battery, part 2: co-
norming and standardization. American Journal of Psychiatry, 165, 214-20. 
Lees, J., Applegate, E., Emsley, R., Lewis, S., Michalopoulou, P., Collier, T., Lopez-
Lopez, C., Kapur, S., Pandina, G. & Drake, R. (2015). Calibration and cross-
validation of MCCB and CogState in schizophrenia. Psychopharmacology (Berl), 
232, 3873-82. 
Michalopoulou, P. G., Lewis, S. W., Drake, R. J., Reichenberg, A., Emsley, R., 
Kalpakidou, A. K., Lees, J., Bobin, T., Gilleen, J. K., Pandina, G., Applegate, E., 
Wykes, T. & Kapur, S. (2015). Modafinil combined with cognitive training: 
pharmacological augmentation of cognitive training in schizophrenia. European 
Neuropsychopharmacology, 25, 1178-89. 
Mohamed, A. D. & Lewis, C. R. (2014). Modafinil increases the latency of response in the 
Hayling Sentence Completion Test in healthy volunteers: a randomised controlled 
trial. PLoS One, 9, e110639. 
14 
 
Müller, U., Rowe, J. B., Rittman, T., Lewis, C., Robbins, T. W. & Sahakian, B. J. (2013). 
Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in 
healthy volunteers. Neuropharmacology, 64, 490-5. 
Nuechterlein, K. H., Green, M. F., Kern, R. S., Baade, L. E., Barch, D. M., Cohen, J. D., 
Essock, S., Fenton, W. S., Frese, F. J., 3rd, Gold, J. M., Goldberg, T., Heaton, R. 
K., Keefe, R. S., Kraemer, H., Mesholam-Gately, R., Seidman, L. J., Stover, E., 
Weinberger, D. R., Young, A. S., Zalcman, S. & Marder, S. R. (2008). The 
MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and 
validity. American Journal of Psychiatry, 165, 203-13. 
Pierre, J. M., Peloian, J. H., Wirshing, D. A., Wirshing, W. C. & Marder, S. R. (2007). A 
randomized, double-blind, placebo-controlled trial of modafinil for negative 
symptoms in schizophrenia. Journal of Clinical Psychiatry, 68, 705-10. 
Randall, D. C., Fleck, N. L., Shneerson, J. M. & File, S. E. (2004). The cognitive-
enhancing properties of modafinil are limited in non-sleep-deprived middle-aged 
volunteers. Pharrmacology, Biochemistry and Behavior, 77, 547-55. 
Randall, D. C., Shneerson, J. M., Plaha, K. K. & File, S. E. (2003). Modafinil affects 
mood, but not cognitive function, in healthy young volunteers. Human 
Psychopharmacology, 18, 163-73. 
Randall, D. C., Viswanath, A., Bharania, P., Elsabagh, S. M., Hartley, D. E., Shneerson, 
J. M. & File, S. E. (2005). Does modafinil enhance cognitive performance in young 
volunteers who are not sleep-deprived? Journal of Clinical Psychopharmacology, 25, 
175-9. 
Reichenberg, A., Caspi, A., Harrington, H., Houts, R., Keefe, R. S., Murray, R. M., 
Poulton, R. & Moffitt, T. E. (2010). Static and dynamic cognitive deficits in 
childhood preceeding adult schizophrenia: a 30-year study. American Journal of 
Psychiatry, 167, 160-9. 
Robbins, T. W., James, M., Owen, A. M., Sahakian, B. J., Lawrence, A. D., Mcinnes, L. 
& Rabbitt, P. M. (1998). A study of performance on tests from the CANTAB battery 
sensitive to frontal lobe dysfunction in a large sample of normal volunteers: 
implications for theories of executive functioning and cognitive aging. Cambridge 
Neuropsychological Test Automated Battery. Journal of the International 
Neuropsychological Society, 4, 474-90. 
Robbins, T. W., James, M., Owen, A. M., Sahakian, B. J., Mcinnes, L. & Rabbitt, P. 
(1994). Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor 
analytic study of a large sample of normal elderly volunteers. Dementia, 5, 266-81. 
Rosenthal, M. H. & Bryant, S. L. (2004). Benefits of adjunct modafinil in an open-label, 
pilot study in patients with schizophrenia. Clinical Neuropharmacology, 27, 38-43. 
Rothman, K. (1990). No adjustments are needed for multiple comparisons. Epidemiology, 1, 
43-46. 
Scoriels, L., Barnett, J. H., Murray, G. K., Cherukuru, S., Fielding, M., Cheng, F., 
Lennox, B. R., Sahakian, B. J. & Jones, P. B. (2011). Effects of modafinil on 
emotional processing in first episode psychosis. Biological Psychiatry, 69, 457-64. 
Scoriels, L., Barnett, J. H., Soma, P. K., Sahakian, B. J. & Jones, P. B. (2012). Effects of 
modafinil on cognitive functions in first episode psychosis. Psychopharmacology 
(Berl), 220, 249-58. 
Scoriels, L., Jones, P. B. & Sahakian, B. J. (2013). Modafinil effects on cognition and 
emotion in schizophrenia and its neurochemical modulation in the brain. 
Neuropharmacology, 64, 168-184. 
Sevy, S., Rosenthal, M. H., Alvir, J., Meyer, S., Visweswaraiah, H., Gunduz-Bruce, H. & 
Schooler, N. R. (2005). Double-blind, placebo-controlled study of modafinil for 
15 
 
fatigue and cognition in schizophrenia patients treated with psychotropic medications. 
Journal of Clinical Psychiatry, 66, 839-43. 
Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., 
Hergueta, T., Baker, R. & Dunbar, G. C. (1998). The Mini-International 
Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured 
diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical 
Psychiatry, 59 Suppl 20, 22-33;quiz 34-57. 
Spence, S. A., Green, R. D., Wilkinson, I. D. & Hunter, M. D. (2005). Modafinil 
modulates anterior cingulate function in chronic schizophrenia. British Journal of 
Psychiatry, 187, 55-61. 
Turner, D. C., Clark, L., Pomarol-Clotet, E., Mckenna, P., Robbins, T. W. & Sahakian, 
B. J. (2004). Modafinil improves cognition and attentional set shifting in patients with 
chronic schizophrenia. Neuropsychopharmacology, 29, 1363-73. 
Turner, D. C., Robbins, T. W., Clark, L., Aron, A. R., Dowson, J. & Sahakian, B. J. 
(2003). Cognitive enhancing effects of modafinil in healthy volunteers. 
Psychopharmacology (Berl), 165, 260-9. 
Vreeker, A., Van Bergen, A. H. & Kahn, R. S. (2015). Cognitive enhancing agents in 
schizophrenia and bipolar disorder. European Neuropsychopharmacology, 25, 969-
1002. 
Wong, Y. N., King, S. P., Simcoe, D., Gorman, S., Laughton, W., Mccormick, G. C. & 
Grebow, P. (1999a). Open-label, single-dose pharmacokinetic study of modafinil 
tablets: influence of age and gender in normal subjects. Journal of Clinical 
Pharmacology, 39, 281-8. 
Wong, Y. N., Simcoe, D., Hartman, L. N., Laughton, W. B., King, S. P., Mccormick, G. 
C. & Grebow, P. E. (1999b). A double-blind, placebo-controlled, ascending-dose 
evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy 
male volunteers. Journal of Clinical Pharmacology, 39, 30-40. 
 
 
  
16 
 
Figure 1 
 
 
  
17 
 
Table 1: Summary of participant characteristics and study variables 
Variables Healthy, n (%) Recent-onset, n (%) 
Site:                                                            0 
21 (100) 
14 (35) 
26 (65) London 
Manchester 
Ethnicity:                                            
16 (76) 
1   (5) 
4 (19) 
 
22 (55) 
15 (37.5) 
3   (7.5) 
White 
Black/African 
Other 
Sex:                                                                  
15 (71) 
6 (29) 
 
30 (75) 
10 (25) 
Male 
Female 
Handedness:   
Right 
  Left 
20 (95) 
1   (5) 
34 (85) 
6 (15) 
Smoker:                                                            
Yes 
No 
14 (67) 
7 (33) 
23 (58) 
17 (42) 
 Healthy Mean (SD) Recent-onset Mean (SD) 
Age 25.81 (4.82) 25.63 (4.92) 
Education, years full time 13.90 (2.74) 12.30 (3.77) 
Chlorpromazine Equivalent - 239.26 (119.37) 
Duration of illness (months) - 21.50 (9.36) 
WTAR Standard Score 110.71 (14.61) 99.43 (13.99) 
PANSS Positive - 13.93 (4.06) 
PANSS Negative - 15.88 (5.61) 
PANSS General - 30.87 (6.27) 
PANSS Total - 60.70 (13.72) 
WTAR – Wechsler Test of Adult Reading, PANSS – Positive And Negative Symptoms Scale 
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Table 2: Summary statistics and modafinil effects for MCCB and selected CANTAB tasks in 
volunteers with schizophrenia 
IED – Intra-Extra Dimensional Set Shift, MOT – Motor Screening, OTS – One Touch Stockings of Cambridge, PAL – Paired Associate 
Learning, RTI – Reaction Time 
 
MCCB Domain 
Modafinil Placebo Treatment effect 
Mean SD Mean SD Mean Effect (95% CI) P-value 
Speed of processing 40.55 14.19 40.21 15.19 0.34 (-2.27, 2.95) 0.801 
Attention/Vigilance 36.74 10.94 35.32 10.56 1.43 (-0.63, 3.48) 0.174 
Working memory 41.47 9.65 39.67 9.79 1.80 (-0.09, 3.69) 0.062 
Verbal learning  41.04 11.36 40.28 10.45 0.75 (-2.70, 4.21) 0.670 
Visual learning 39.75 12.54 42.29 12.12 -2.54 (-5.71, 0.64) 0.117 
Reasoning & problem solving 44.30 11.13 43.65 10.77 0.65 (-1.70, 3.00) 0.590 
Social cognition 40.19 11.52 38.76 9.41 1.43 (-0.85, 3.71) 0.220 
MCCB Composite 34.73 13.79 33.73 13.53 0.99 (-1.21, 3.20) 0.378 
       
CANTAB variable       
IED Errors Adjusted 32.25 29.17 28.09 21.52 4.16 (3.90, 12.23) 0.311 
IED Stages completed 8.26 1.22 8.45 0.85 -0.20 (-0.56, 0.16) 0.284 
MOT Mean Latency, s 808.62 152.11 843.41 175.31 -34.8 (-99.3, 28.7) 0.282 
MOT Median error 764.98 139.33 800.39 153.78 -35.41 (-88.42, 17.60) 0.190 
MOT Mean Error 7.29 2.26 7.71 2.17 -0.43 (-1.04, 0.18) 0.168 
OTS Problems solved on first choice 9.80 2.54 9.35 2.89 0.46 (-0.24, 1.16) 0.202 
OTS choices to correct 1.61 0.42 1.69 0.52 -0.08 (-0.18, 0.02) 0.105 
OTS mean latency to correct, s 21127.5 9581.85 18471 6678.49 2656 (552, 4760) 0.013 
OTS median latency to correct, s 17279.5 10078.33 13983 6275.19 3297 (758, 5835) 0.011 
PAL total errors adjusted 16.12 17.44 19.00 22.98 -2.88 (-6.24, 0.48) 0.093 
PAL errors 6 shapes adjusted 3.16 5.34 4.56 6.39 -1.40 (-2.54, -0.27) 0.015 
RTI simple accuracy score 28.77 1.17 28.91 1.39 -0.14 (-0.61, 0.33) 0.553 
RTI mean simple reaction time, s 327.39 82.36 318.78 65.32 8.60 (-6.88, 24.09) 0.276 
RTI median simple reaction time, s 307.41 63.02 304.97 61.89 2.44 (-7.30, 12.18) 0.623 
RTI SD simple reaction time, s 89.45 117.37 63.90 30.07 25.5 (-7.8, 58.8) 0.134 
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Table 3: Summary statistics and treatment effects for MCCB and CANTAB in healthy volunteers  
MCCB Domain 
Modafinil Placebo Treatment Effects 
Mean SD Mean SD Mean Effect (95% CI)  P-value 
Speed of processing 62.01 12.70 60.07 12.48 1.99 (-0.78, 4.75) 0.159 
Attention/Vigilance 41.93 14.70 42.56 13.01 -0.63 (-5.12, 3.87) 0.785 
Working memory 49.86 10.19 49.00 10.23 0.86 (-1.47, 3.19) 0.469 
Verbal learning  42.91 9.33 44.46 10.93 -1.56 (-4.69, 1.58)  0.331 
Visual learning 49.41 9.04 47.21 8.10 2.21 (-0.39, 4.80) 0.095 
Reasoning and problem solving 53.24 8.35 53.97 8.66 -0.74 (-4.71, 3.24)  0.716 
Social cognition 54.11 8.19 49.07 6.54 5.04 (2.23, 7.86) <0.001 
MCCB Composite 50.60 11.41 48.98 12.14 1.63 (-0.23, 3.48) 0.085 
       
CANTAB variable       
IED Total Errors Adjusted 18.11 18.99 22.56 22.00 -4.44 (-7.74, -1.15)  0.008 
IED Stages completed 8.86 0.48 8.63 0.87 0.24 (-0.04, 0.51)  0.095 
MOT Mean Latency 696.62 170.99 743.53 199.98 -40.72 (-95.17, 13.74)  0.143 
MOT Median error 663.88 154.19 704.60 195.03 -0.89 (-2.05, 0.28)  0.136 
OTS solved on first choice 10.96 2.29 11.04 2.32 -0.08 (-0.81, 0.64)  0.822 
OTS choices to correct 1.41 0.31 1.41 0.32 -0.00 (-0.08, 0.08)  0.965 
OTS median latency to correct 10232.5 3614.45 10442.5 3011.38 -210 (-1533, 1114)  0.756 
PAL total errors adjusted 7.6 7.30 9.96 13.18 -2.36 (-6.51, 1.79)  0.265 
PAL total errors 6 shapes adjusted 1.29 2.06 1.32 1.85 -0.03 (-0.97, 0.92)  0.954 
RTI simple accuracy score 28.74 1.50 29.17 0.87 -0.43 (-1.16, 0.30)  0.249 
RTI median simple reaction time, s 279.76 33.37 286.67 38.31 -6.91 (-20.38, 6.56)  0.315 
RTI 5 choice accuracy score 29.56 0.60 29.51 0.75 0.04 (-0.34, 0.42)  0.831 
RTI 5 choice reaction time, s 314.00 56.94 308.70 39.92 5.30 (-9.64, 20.24)  0.487 
RVP A’ 0.95 0.04 0.92 0.05 0.02 (0.01, 0.03) 0.004 
RVP Probability of hit 0.78 0.14 0.72 0.17 0.07 (0.03, 0.11) 0.001 
RVP median latency 378.46 37.71 387.82 49.09 -9.36 (-24.70, 5.98)  0.232 
SWM Strategy 13.25 4.15 13.86 4.09 -0.61 (-1.85, 0.63)  0.335 
VRM: Free recall correct 
immediate 
8.46 1.81 8.10 2.30 0.36 (-0.47, 1.19)  0.393 
VRM: Free recall novel words 
immediate 
0.09 0.30 0.37 0.58 -0.27 (-0.53, -0.03) 0.028 
VRM: Recognition correct 
immediate 
23.07 1.16 23.38 1.40 0.19 (-0.33, 0.72) 0.467 
VRM: Recognition correct delayed 22.95 1.47 22.36 1.96 0.58 (-0.07, 1.24) 0.081 
IED – Intra-Extra Dimensional Set Shift, MOT – Motor Screening, OTS – One Touch Stockings of Cambridge, PAL – Paired Associate 
Learning, RTI – Reaction Time, RVP – Rapid Visual Information Processing, SWM – Spatial Working Memory, VRM – Verbal Recognition 
Memory 
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Table 4: Comparison of modafinil effects between healthy volunteers and patients on MCCB 
MCCB Domain Interaction effect 
Effect (SE) P-value 95% CI 
MCCB Composite 0.67 (1.69) 0.694 -2.65, 3.98 
Speed of processing 1.62 (2.09) 0.437 -2.47, 5.72 
Attention/Vigilance -2.01 (2.18) 0.356 -6.27, 2.26 
Working memory -0.93 (1.57) 0.555 -4.01, 2.15 
Verbal learning  -2.23 (2.69) 0.407 -7.50, 3.04 
Visual learning 4.89 (2.46) 0.047 0.07, 9.71 
Reasoning and problem solving -1.45 (2.20) 0.510 -5.75, 2.86 
Social cognition 3.57 (1.90) 0.060 -0.15, 7.30 
  
 
 
